Abstracts

COST-EFFECTIVENESS OF CRAG SCREENING FOR PLHIV WITH ADVANCED HIV DISEASE IN MALAWI

Background: Cryptococcal meningitis (CM) remains a leading cause of death among PLHIV; diagnosis and treatment of asymptomatic cryptococcal disease can prevent progression to symptomatic CM. We projected the clinical impact and cost-effectiveness of cryptococcal antigen (CrAg) screening with pre-emptive fluconazole therapy in PLHIV with CD4 < 200/µL and no meningitis symptoms initiating ART in Malawi.…

Ag-RDT MASS TESTING IN LARGE GATHERINGS TO IDENTIFY SARS-CoV-2 INFECTIONS IN KENYA

Background: In Africa, the 9.3 million COVID-19 cases and 174,993 related deaths reported between 2020 and 2022 are underestimated given the limited testing and reporting capacity. Mass testing with antigen-detecting rapid diagnostic tests (Ag-RDTs), including testing of asymptomatic individuals, is expected to improve the identification of SARS-CoV-2 infections and enable immediate clinical management, isolation of…

AUTOMATED LIVER ATTENUATION ASSESSMENT FOR STEATOSIS IN CLINICAL IMAGES BY HIV STATUS

Background: The study of hepatic steatosis in HIV has been limited due to lack of direct diagnostic evaluations in real-world cohorts. Artificial intelligence offers tools to automate identification of hepatic steatosis within radiographic images for use in epidemiologic studies that examine associations with important risk factors and outcomes. We applied the Automatic Liver Attenuation Region-of-Interest-based…

TIXAGEVIMAB/CILGAVIMAB IM AND IV FOR COVID-19: A RANDOMIZED CONTROLLED ACTIV-2 TRIAL

Background: Within the ACTIV-2/A5401 platform (NCT04518410), the safety and efficacy of tixagevimab/cilgavimab (T/C), an anti-SARS-CoV-2 monoclonal antibody combination, was studied in outpatients with COVID-19. Intravenous (IV) and intramuscular (IM) administration of T/C were assessed. Methods: Non-hospitalized adults ≥18 years enrolled within 10 days of positive SARS-CoV-2 test and symptom onset. Participants at higher risk of…

SARS-COV-2 SEROPREVALENCE BY HIV STATUS AMONG PREGNANT WOMEN IN ZAMBIA, 2021-2022

Background: People living with HIV (PLHIV), though at no greater risk of SARS-CoV-2 infection, are at increased risk of severe COVID-19 and have been prioritized for COVID-19 mitigation strategies in Zambia. Evidence suggests that the natural and vaccine-derived immune response among PLHIV may be less durable compared to immunocompetent populations. We measured SARS-CoV-2 seroprevalence and…